Daiichi Sankyo Company, Limited DSNKY
17.51 USD -0.17 (-0.96%)
Nov 11, 2026, 3:47 PM EST
17.38 Day range 17.54
14.98 52-week range 24.77
- YTD
- -17.56%
- 1 year
- -20.81%
News
benzinga.com Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1 Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU…
benzinga.com AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.
benzinga.com Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer
benzinga.com Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial 6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression…- benzinga.com Organon Signs Commercialization Agreement For Daiichi Sankyo's Nilemdo To Strengthen Cardiovascular Disease Portfolio In France And Nordic Countries The agreement builds on Organon's cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This…
- benzinga.com Earnings Scheduled For July 31, 2020 Companies Reporting Before The Bell • Chevron Inc. (NYSE:CVX) is expected to report quarterly loss at $0.92 per share on revenue of $22.10 billion. • Weyerhaeuser Inc. (NYSE:WY) is estimated to…
benzinga.com Stocks That Hit 52-Week Highs On Thursday 
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Monday - benzinga.com Stocks That Hit 52-Week Highs On Friday
benzinga.com Stocks That Managed to Breach 52-Week Highs Wednesday Morning